Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study [0.03%]
长期剂量变化及五年真实世界研究中难治性抑郁患者的临床结局分析-艾司氯胺酮鼻喷雾剂治疗难治性抑郁症：一项为期五年的观察性研究中的长期给药模式和临床结果分析
Alessandro Cuomo,Roger McIntyre,Despoina Koukouna et al.
Alessandro Cuomo et al.
Background: Treatment-resistant depression (TRD) remains a major clinical challenge, and long-term real-world data on intranasal esketamine are limited. O...
Adult psychiatrists' views on clozapine prescribing for schizophrenia in Germany-an online survey [0.03%]
德国成人精神病医师关于使用氯氮平治疗精神分裂症的见解——一项在线调查
Mishal Qubad,Ida Marie Ehret,Christian J Bachmann et al.
Mishal Qubad et al.
Background: Clozapine remains the only effective antipsychotic drug for treatment-resistant schizophrenia (TRS), yet it continues to be markedly underused in most industrialized countries including Germany. Previous studi...
Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system [0.03%]
韩国氯氮平所致中性粒细胞减少症和粒细胞缺乏症的2025年更新：重新思考监测系统的作用
Nuree Kang,Ji Seon Jang,Sung Woo Joo et al.
Nuree Kang et al.
Background: In February 2025, the FDA ended the mandatory Risk Evaluation and Mitigation Strategy requirements for clozapine. Korea continues mandatory hematologic testing under the Clozapine Patient Monitoring System (CP...
Maura DiSalvo,Joseph Biederman,Hannah O&#x;Connor et al.
Maura DiSalvo et al.
Background: Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by inattentiveness and/or hyperactivity and increased impulsivity. A common treatment for ADHD is stimulant medications, with a formulation ...
MicroRNAs in metabolic effects with atypical antipsychotics-a scoping review [0.03%]
与非典型抗精神病药物的代谢作用相关的微小核糖核酸-综述性研究
Weng Tong Wu,Deonna Setiawan,Stephen J Glatt et al.
Weng Tong Wu et al.
Background: Metabolic side effects associated with atypical antipsychotics represent a major challenge in the clinical management of schizophrenia, contributing to poor treatment adherence and an increased risk of relapse...
Effects of cariprazine on cholesterol, glucose, and weight in patients with schizophrenia: a systematic review and meta-analysis [0.03%]
卡利拉嗪对精神分裂症患者胆固醇、血糖和体重影响的系统评价和meta分析
Isabella Berardelli,Mariarosaria Cifrodelli,Attilio Valerio Mammoliti et al.
Isabella Berardelli et al.
Background: Cariprazine is a second-generation antipsychotic approved for treating schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, and major depressive disorder. Antipsychotic treatment is...
A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations [0.03%]
一项范围性审查：迷幻疗法临床试验中的神秘型体验与情绪症状结果：将生命威胁性疾病人群和抑郁症人群进行比较
Ana Deutsch,Luis E Contreras,Sarah Kratina et al.
Ana Deutsch et al.
Background: Psychedelic therapies are gaining attention as tools to alleviate anxiety and depression across various clinical populations. However, the mechanisms behind psychedelics' therapeutic efficacy and the potential...
Clinical hallmarks and peripheral immune factors associated with antipsychotic-induced constipation in schizophrenia [0.03%]
精神分裂症抗精神病药物所致便秘的临床特征及外周免疫因素
Miaomiao Shao,Tingting Zhu,Xiuxiu Hu et al.
Miaomiao Shao et al.
Background: Constipation is a frequent adverse effect of antipsychotic treatment in schizophrenia. Objectives: This study aimed to inve...
Adjunctive xanomeline/trospium in clozapine-resistant schizophrenia: two case reports demonstrating limited response [0.03%]
氯氮平治疗抵抗的精神分裂症患者使用曲潘米奈/屈司匹明作为增效药物：两例病例报告表明有限的疗效响应
Vanessa M Dang,John M Powers,Matej Markota et al.
Vanessa M Dang et al.
Few pharmacologic options exist for patients with clozapine-resistant schizophrenia (CRS) or schizoaffective disorder. Xanomeline/trospium represents a new class of antipsychotic medication that has efficacy as monotherapy for schizophrenia...
A rapid clinical response to etifoxine in treatment-resistant obsessive-compulsive disorder: a case report of a patient with comorbid bipolar disorder [0.03%]
氯羟azino治疗难治性强迫症的快速临床反应——一名合并双相情感障碍患者的病例报告
Pornjira Pariwatcharakul,Punyisa Prachgosin
Pornjira Pariwatcharakul
This case report describes the rapid clinical response to etifoxine, an oral translocator protein 18 kDa (TSPO) ligand, in a patient with severe, treatment-resistant obsessive-compulsive disorder (OCD) with comorbid bipolar I disorder. Desp...